Background: These benign tumors are the most frequent in women, with an estimated lifetime risk of 70–80% before menopause. Laparoscopic myomectomy (LM) had less postoperative discomfort, lesser postoperative fever, and a decreased hospital stay than open myomectomy. However, control of blood loss is meanwhile a persistent challenge. Many drugs were investigated to minimize blood loss during myomectomy. Methylergonovine is used to treat postpartum uterine hemorrhage. Objective: to see whether a methylergonovine peri-operative infusion may help reduce loss of blood during a laparoscopic myomectomy. 
Patients and methods: The Obstetrics and Gynecology Department of Benha University performed this randomized controlled research. It was involved 80 patients allocated either into group A treated with methylergonovine infusion or group B receiving placebo in the form of normal saline.   Results: In baseline parameters, there was no substantial variation among  the two groups. The length of the surgery projected intra-operative bleeding, post-operative hemoglobin, post-operative hematocrit, number of packed RBC units transfused, and postoperative hospital stay were all substantially different between the two groups. In the number of patients who need blood transfusions, there was a substantial variation. When it came to the negative effects of methylergonovine, there was no substantial difference. Conclusion: During laparoscopic myomectomy, methylergonovine infusion greatly decreased loss of blood and the requirement for blood transfusions.